ABTI
Price:
$0.0053
Market Cap:
$7.74M
Alterola Biotech, Inc., a pharmaceutical company, engages in the development of cannabinoid and cannabinoid-like molecules. It focuses on the development of regulated human and animal health pharmaceuticals and regulated food products; production of active pharmaceutical ingredients and food-grade ingredients; and formulation and drug delivery for improved bioavailability, solubility, and stability. The company is based in Birkenhead, the United Kingdom.[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2010-05-05
Stock Exchange
PNK
Ticker
ABTI
According to Alterola Biotech, Inc.’s latest financial reports and current stock price. The company's current ROE is -20.20%. This represents a change of 1.78% compared to the average of -1.07% of the last 4 quarters.
The mean historical ROE of Alterola Biotech, Inc. over the last ten years is 47.33%. The current -20.20% ROE has changed -142.67% with respect to the historical average. Over the past ten years (40 quarters), ABTI's ROE was at its highest in in the September 2018 quarter at 612.65%. The ROE was at its lowest in in the June 2018 quarter at -2344.96%.
Average
47.33%
Median
27.99%
Minimum
-59.23%
Maximum
239.47%
Discovering the peaks and valleys of Alterola Biotech, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 719.29%
Maximum Annual ROE = 239.47%
Minimum Annual Increase = -211.61%
Minimum Annual ROE = -59.23%
Year | ROE | Change |
---|---|---|
2023 | -15.28% | -74.20% |
2022 | -59.23% | -211.61% |
2020 | 53.06% | -58.42% |
2019 | 127.62% | -46.71% |
2018 | 239.47% | 719.29% |
2017 | 29.23% | 241.85% |
2016 | 8.55% | -42.85% |
2015 | 14.96% | -44.06% |
2014 | 26.74% | -44.51% |
2013 | 48.20% | 318.04% |
The current ROE of Alterola Biotech, Inc. (ABTI) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-7.15%
5-year avg
69.13%
10-year avg
47.33%
Alterola Biotech, Inc.’s ROE is less than Amexdrug Corporation (0%), less than Aion Therapeutic Inc. (0.09%), less than Aspen Pharmacare Holdings Limited (60.85%), less than Antisense Therapeutics Limited (0.44%), greater than The BC Bud Corporation (-109.43%), greater than Crescita Therapeutics Inc. (-171.61%), greater than null (-16.29%),
Company | ROE | Market cap |
---|---|---|
0% | $338.82K | |
0.09% | $2.39M | |
60.85% | $5.44B | |
0.44% | $92.64M | |
-109.43% | $781.33K | |
-171.61% | $8.61M | |
-16.29% | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Alterola Biotech, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Alterola Biotech, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Alterola Biotech, Inc.'s ROE?
How is the ROE calculated for Alterola Biotech, Inc. (ABTI)?
What is the highest ROE for Alterola Biotech, Inc. (ABTI)?
What is the 3-year average ROE for Alterola Biotech, Inc. (ABTI)?
What is the 5-year average ROE for Alterola Biotech, Inc. (ABTI)?
How does the current ROE for Alterola Biotech, Inc. (ABTI) compare to its historical average?